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Background  
Cardiovascular disease risk factors (CVDRF) are prevalent in people 
living with HIV (PLHIV), but the optimal clinical management strategy 
for patients with both HIV and CVDRF in low-resource settings is 
unknown. In some contexts, care for both HIV and CVDRF is provided 
in the HIV clinic (“integrated care”), which may be more convenient for 
patients. In others, PLHIV are referred to specialist clinics for 
management of their CVDRF (“referred care”) which may lead to higher 
quality CVDRF management (Figure 1). We compared integrated vs. 
referred strategies for patients with HIV and CVDRF at an urban health 
facility in Swaziland, exploring linkage to and retention in CVDRF care, 
intervention fidelity, and HIV and CVDRF-related health outcomes. 
Methods 
HIV-positive patients attending HIV clinic visits at Raleigh Fitkin 
Memorial Hospital in Manzini, Swaziland were eligible for screening for 
CVDRF if they:  
•  Had been on ART for at least a year 
•  Were ≥ 40 years of age   
•  Had no history of CVD 
•  Were not pregnant or acutely ill 
CVDRF screening included:  
•  Resting BP measurement x 2 to screen for hypertension (HTN)  
•  Point-of-care HbA1c test to screen for diabetes mellitus (DM)   
•  Point-of-care total cholesterol test to screen for hyperlipidemia (HL) 
•  Assessment of tobacco smoking via self-report 
•  Assessment of ten-year CVD risk via WHO/ISH risk stratification   
Patients with HTN and/or > 10% ten-year CVD risk were randomized 
1:1 to receive CVDRF management at HIV clinic (integrated arm) or 
outpatient clinic (referred arm) for 6 months (Figure 2). 
Conclusion 
Among ppts with both HIV and CVDRF, linkage to CVDRF care following 
screening was high regardless of the management strategy assigned. Ppts 
demonstrated a preference for integrated care, as evidenced by lower 
adherence with the REF management strategy.  
Marked improvements in SBP and HbA1c were noted in both arms among 
ppts started on medication for CVDRF during the study while slight 
improvement in TC was seen only in the REF arm.   
Retention in HIV care was high in both arms, with no difference between 
patients receiving INT vs. REF management. In contrast, retention in 
CVDRF care was modest in both arms. This could be due either to 
discontinuation of CVDRF management or discontinuation of documentation 
of CVDRF management; the latter is more likely given the sustained 
improvement in CVDRF.   
The study showed that one-quarter of HIV patients ≥ 40 years on ART at 
Raleigh Fitkin Memorial Hospital had HTN and/or ≥ 10% ten-year CVD risk. 
Substantial improvements in BP and diabetes control were achieved 
irrespective of management strategy, suggesting that such comorbidities 
can be effectively managed by HIV providers. 
ICAP at Columbia University’s Mailman School of Public Health was founded in 2003. ICAP works around 
the world to promote the health and well being of communities. ICAP partners with ministries of health, non-
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Figure 2. Flowchart of study enrollment 








Male  82 (34%) 41 (33%) 41 (35%) 0.78 
Age, median (IQR) 51 (45-59) 52 (45-60) 50 (45-56) 0.40 
Secondary education or higher 110 (46%) 47 (38%) 63 (54%) 0.02 
BMI at screening, median (IQR) 28 (25-32) 28 (24-32) 29 (26-33) 0.06 
≥5 years since HIV diagnosis 181 (75%) 97 (79%) 84 (72%) 0.45 
≥3 years on ART 194 (82%) 99 (82%) 95 (82%) 0.06 
CVD risk factors 
     Hypertension 218 (91%) 113 (92%) 105 (89%) 0.47 
     Hyperlipidemia 40 (17%) 22 (18%) 18 (15%) 0.60 
     Diabetes 35 (15%) 20 (16%) 15 (13%) 0.45 
     Tobacco smoking (self-report) 9 (4%) 6 (5%) 3 (3%) 0.35 
≥10% 10-year CVD risk 24 (10%) 14 (11%) 10 (9%) 0.46 
Secondary outcomes (intervention fidelity): 
•  Ppts in each arm had an average of 2.3 and a median of 2.0 visits in 
which CVDRF services were documented during the 6 months of the 
study   
•  Adherence with assigned study arm was higher in the INT vs. REF 
arms (86% vs. 68%, RR [CI]: 1.28 [1.10, 1.47]). 
Secondary outcomes (HIV and CVDRF outcomes): 
•  184/218 ppts with HTN were not on BP meds at baseline. Of these 
122/184 (66%) initiated BP meds during the study.  
•  A higher proportion of eligible ppts with HTN initiated BP meds in 
the INT arm (72% of those not on BP meds) than the REF arm (53% 
of those not on BP meds) (RR [95% CI]: 1.35 [1.07, 1.69]). 
•  Amongst ppts with HTN, there was a statistically significant mean 
reduction in SBP at 6 months in both study arms (-15 mmHg in both 
arms), but no statistically significant difference between arms. The 
median (IQR) change was –14 (-26.5, -3.5) in the INT arm and -17 
(-25.5, -6) in the REF arm. 
•  Amongst the 35 ppts with DM, 9 initiated DM medication. There was 
a statistically significant mean reduction of -0.68% in HbA1c (CI: 
-1.26, -0.10) and -1.37% in HbA1c  (-2.51, -0.24) in the INT and 
REF arms, respectively with no statistical difference between arms. 
•  Amongst the 40 ppts with HL,18 initiated medication. There was a 
statistically significant mean reduction in TC of -0.91 mmol/L (CI 
-1.76, -0.65) in the REF arm and no significant Δ in the INT arm. 
Figure 1. Integrated vs. referred CVDRF management 
The primary study outcome was a composite measure of linkage to 
CVDRF care and retention in both CVDRF and HIV management:  
ü  Linkage to CVDRF care within one month AND 
ü  Documented receipt of CVDRF services at six months AND 
ü  Retention in HIV care at six months 
Secondary outcomes included:  
ü  Number of CVDRF management visits attended 
ü  Adherence with assigned study arm 
ü  Medication initiation (when indicated) 
ü  Change (Δ) in systolic blood pressure (SBP), glycated hemoglobin 
(HbA1c), and total cholesterol (TC) 
Figure 3. CVDRF linkage and CVDRF + HIV retention 
Results 
240 participants (ppts) were enrolled. Baseline characteristics were 
similar in both arms, with the exception of the percent with post-primary 
education, which was higher in the referred (REF) vs. integrated (INT) 
arm (54% vs. 38%) (p=0.02) (Table 1). 
 
Primary outcome:  
There was no difference in the primary outcome between arms (Figure 
3). Linkage to CVDRF care within one month was achieved by 85% and 
84% of ppts in the INT and REF arms, respectively. While at 6 months 
follow-up only 20% of ppts in INT and 21% in REF arms continued to 
receive documented CVDRF services, retention in HIV care was 98% in 
both arms.  
Figure 4. Changes in CVDRF 
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